Last reviewed · How we verify
Antithrombotic Agent
Antithrombotic agents prevent blood clot formation by inhibiting platelet aggregation or coagulation cascade pathways.
Antithrombotic agents prevent blood clot formation by inhibiting platelet aggregation or coagulation cascade pathways. Used for Thrombotic and thromboembolic disorders (general class indication).
At a glance
| Generic name | Antithrombotic Agent |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Antithrombotic Agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antithrombotic agents work through multiple mechanisms including platelet inhibition (e.g., antiplatelet drugs like aspirin or P2Y12 inhibitors), anticoagulation (e.g., warfarin, direct oral anticoagulants), or thrombin inhibition. These drugs reduce the risk of pathological thrombosis in arterial and venous systems by interfering with hemostatic mechanisms.
Approved indications
- Thrombotic and thromboembolic disorders (general class indication)
Common side effects
- Bleeding
- Hemorrhage
- Gastrointestinal bleeding
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE (NA)
- Optimizing Reperfusion to Improve Outcomes and Neurologic Function (PHASE2, PHASE3)
- TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antithrombotic Agent CI brief — competitive landscape report
- Antithrombotic Agent updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI